Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Im ersten Live-Webinar unserer neuen Veranstaltungsreihe im Rahmen der Initiative DiAd gegen gegen Typ-2-Diabetes und Adipositas von Springer Medizin am 13. Juni von 17.30 bis 19 Uhr werfen wir einen interdisziplinären Blick auf die Herausforderungen und Chancen in der Primärversorgung von Menschen mit Adipositas und beleuchten auch die Perspektive der Betroffenen. Jetzt hier kostenlos anmelden und 2 CME-Punkte einsammeln.
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 5/2016

05.02.2016 | Review

Quantitative Imaging Biomarkers of NAFLD

verfasst von: Sonja Kinner, Scott B. Reeder, Takeshi Yokoo

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Conventional imaging modalities, including ultrasonography (US), computed tomography (CT), and magnetic resonance (MR), play an important role in the diagnosis and management of patients with nonalcoholic fatty liver disease (NAFLD) by allowing noninvasive diagnosis of hepatic steatosis. However, conventional imaging modalities are limited as biomarkers of NAFLD for various reasons. Multi-parametric quantitative MRI techniques overcome many of the shortcomings of conventional imaging and allow comprehensive and objective evaluation of NAFLD. MRI can provide unconfounded biomarkers of hepatic fat, iron, and fibrosis in a single examination—a virtual biopsy has become a clinical reality. In this article, we will review the utility and limitation of conventional US, CT, and MR imaging for the diagnosis NAFLD. Recent advances in imaging biomarkers of NAFLD are also discussed with an emphasis in multi-parametric quantitative MRI.
Literatur
1.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.CrossRefPubMed
2.
Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012;32:1242–1252.CrossRefPubMed
3.
Lupsor M, Badea R. Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy? Rom J Gastroenterol. 2005;14:419–425.PubMed
4.
Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21:87–97.CrossRefPubMedPubMedCentral
5.
Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol (WJG). 2014;20:6821–6825.CrossRef
6.
Hamaguchi M, Kojima T, Itoh Y, et al. The Severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–2715.CrossRefPubMed
7.
Shannon A, Alkhouri N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr. 2011;53:190–195.CrossRefPubMedPubMedCentral
8.
van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256:159–168.CrossRefPubMed
9.
Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques—initial experience. Radiology. 2005;237:507–511.CrossRefPubMed
10.
Bohte AE, Koot BG, van der Baan-Slootweg OH, et al. US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents. Radiology. 2012;262:327–334.CrossRefPubMed
11.
Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol. 2007;189:W320–W323.CrossRef
12.
Cengiz M, Sentürk S, Cetin B, Bayrak AH, Bilek SU. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med. 2014;7:5453–5460.PubMedPubMedCentral
13.
Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061–1067.CrossRefPubMed
14.
Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med. 2009;48:739–746.CrossRefPubMed
15.
Lu ZF, Zagzebski JA, Lee FT. Ultrasound backscatter and attenuation in human liver with diffuse disease. Ultrasound Med Biol. 1999;25:1047–1054.CrossRefPubMed
16.
Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol. 2009;192:909–914.CrossRef
17.
Xia MF, Yan HM, He WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity. 2011;20:444–452.CrossRefPubMedPubMedCentral
18.
Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.CrossRefPubMed
19.
Sasso M, Audière S, Kemgang A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol. 2016;42:92–103.CrossRefPubMed
20.
Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan®. Clin Res Hepatol Gastroenterol. 2012;36:13–20.CrossRefPubMed
21.
de Lédinghen V, Wong GL-H, Vergniol J, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2015. doi:10.​1111/​jgh.​13219.
22.
Boyce CJ, Pickhardt PJ, Kim DH, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. Am J Roentgenol. 2010;194:623–628.CrossRef
23.
Pickhardt P, Park S, Hahn L, Lee S-G, Bae K, Yu E. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22:1075–1082.CrossRefPubMed
24.
Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver. Am J Roentgenol. 2007;188:1307–1312.CrossRef
25.
Park YS, Park SH, Lee SS, et al. Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology. 2011;258:760–766.CrossRefPubMed
26.
Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105–112.CrossRefPubMed
27.
Birnbaum BA, Hindman N, Lee J, Babb JS. Multi-detector row CT attenuation measurements: assessment of intra- and inter-scanner variability with an anthropomorphic body CT phantom. Radiology. 2007;242:109–119.CrossRefPubMed
28.
Fritz GA, Schoellnast H, Deutschmann HA, et al. Density histogram analysis of unenhanced hepatic computed tomography in patients with diffuse liver diseases. J Comput Assist Tomogr. 2006;30:201–205.CrossRefPubMed
29.
Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenol. 1998;171:659–664.CrossRef
30.
Johnston RJ, Stamm ER, Lewin JM, Hendrick RE, Archer PG. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging. 1998;23:409–415.CrossRefPubMed
31.
Zheng X, Ren Y, Phillips WT, et al. Assessment of hepatic fatty infiltration using spectral computed tomography imaging: a pilot study. J Comput Assist Tomogr. 2013;37:134–141.CrossRefPubMed
32.
Artz NS, Hines CDG, Brunner ST, et al. Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse. Invest Radiol. 2012;47:603–610.CrossRefPubMedPubMedCentral
33.
34.
Merkle EM, Nelson RC. Dual gradient-echo in-phase and opposed-phase hepatic MR imaging: a useful tool for evaluating more than fatty infiltration or fatty sparing. Radiographics. 2006;26:1409–1418.CrossRefPubMed
35.
Kang BK, Yu ES, Lee SS, et al. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol. 2012;47:368–375.CrossRefPubMed
36.
Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Mendez-Sanchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol. 2008;7:212–220.PubMed
37.
Henninger B, Zoller H, Rauch S, et al. Automated two-point dixon screening for the evaluation of hepatic steatosis and siderosis: comparison with R2*-relaxometry and chemical shift-based sequences. Eur Radiol. 2015;25:1356–1365.CrossRefPubMed
38.
Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22–29.CrossRefPubMedPubMedCentral
39.
Rehm J, Wolfgram P, Hernando D, Eickhoff J, Allen D, Reeder S. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. Eur Radiol. 2015;25:2921–2930.CrossRefPubMed
40.
41.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–1044.CrossRefPubMed
42.
Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.CrossRefPubMed
43.
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457.CrossRefPubMed
44.
Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012;36:1011–1014.CrossRefPubMedPubMedCentral
45.
Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34:729–749.CrossRefPubMed
46.
Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization of the liver fat H MR spectrum. NMR Biomed. 2011;24:784–790.CrossRefPubMed
47.
48.
Hu HH, Kim HW, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity. 2010;18:841–847.CrossRefPubMedPubMedCentral
49.
Parente DB, Rodrigues RS, Paiva FF, et al. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One. 2014;9:e112574.CrossRefPubMedPubMedCentral
50.
Yokoo T, Bydder M, Hamilton G, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251:67–76.CrossRefPubMedPubMedCentral
51.
Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011;258:767–775.CrossRefPubMedPubMedCentral
52.
Idilman IS, Keskin O, Celik A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol. 2015. doi:10.​1177/​0284185115580488​.PubMed
53.
Hines CD, Yu H, Shimakawa A, McKenzie CA, Brittain JH, Reeder SB. T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging. 2009;30:1215–1222.CrossRefPubMedPubMedCentral
54.
Bydder M, Yokoo T, Hamilton G, et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging. 2008;26:347–359.CrossRefPubMedPubMedCentral
55.
Bannas P, Kramer H, Hernando D, et al. Quantitative magnetic resonance imaging of hepatic steatosis: validation in ex vivo human livers. Hepatology. 2015;62:1444–1455.CrossRefPubMed
56.
Hines CD, Yu H, Shimakawa A, et al. Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology. 2010;254:119–128.CrossRefPubMedPubMedCentral
57.
Runge J, Bakker P, Gaemers I, et al. Measuring liver triglyceride content in mice: non-invasive magnetic resonance methods as an alternative to histopathology. Magn Reson Mater Phys Biol Med. 2014;27:317–327.CrossRef
58.
Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422–431.CrossRefPubMedPubMedCentral
59.
Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267:767–775.CrossRefPubMed
60.
Kukuk G, Hittatiya K, Sprinkart A, et al. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. Eur Radiol. 2015;25:2869–2879.CrossRefPubMed
61.
Tang A, Desai A, Hamilton G, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274:416–425.CrossRefPubMedPubMedCentral
62.
Heba ER, Desai A, Zand KA, et al. Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. J Magn Reson Imaging. 2016;43:398–406.CrossRefPubMedPubMedCentral
63.
Hu HH, Bornert P, Hernando D, et al. ISMRM workshop on fat-water separation: insights, applications and progress in MRI. Magn Reson Med. 2012;68:378–388.CrossRefPubMedPubMedCentral
64.
Ligabue G, Besutti G, Scaglioni R, Stentarelli C, Guaraldi G. MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quant Imaging Med Surg. 2013;3:192–195.PubMedPubMedCentral
65.
Reeder SB. Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology. 2013;58:1877–1880.CrossRefPubMed
66.
Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;61:1887–1895.CrossRefPubMed
67.
Kang GH, Cruite I, Shiehmorteza M, et al. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging. 2011;34:928–934.CrossRefPubMedPubMedCentral
68.
Tyagi A, Yeganeh O, Levin Y, et al. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdom Imaging. 2015;40:3070–3077.CrossRefPubMedPubMedCentral
69.
Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930–1940.CrossRefPubMedPubMedCentral
70.
Idilman IS, Keskin O, Elhan AH, Idilman R, Karcaaltincaba M. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease. Scand J Gastroenterol. 2014;49:617–624.CrossRefPubMed
71.
Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83–95.CrossRefPubMed
72.
Zand KA, Shah A, Heba E, et al. Accuracy of multiecho magnitude-based MRI (M-MRI) for estimation of hepatic proton density fat fraction (PDFF) in children. J Magn Reson Imaging. 2015;42:1223–1232.CrossRefPubMed
73.
Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239–1250.CrossRefPubMedPubMedCentral
74.
Le T-A, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56:922–932.CrossRefPubMedPubMedCentral
75.
Arulanandan A, Ang B, Bettencourt R, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:1513-20.e1.CrossRefPubMed
76.
Wolfgram PM, Connor EL, Rehm JL, Eickhoff JC, Reeder SB, Allen DB. Ethnic differences in the effects of hepatic fat deposition on insulin resistance in non-obese middle school girls. Obesity. 2014;22:243–248.CrossRefPubMedPubMedCentral
77.
Hur BY, Lee JM, Hyunsik W, et al. Quantification of the fat fraction in the liver using dual-energy computed tomography and multimaterial decomposition. J Comput Assist Tomogr. 2014;38:845–852.CrossRefPubMed
78.
Lin SC, Heba E, Wolfson T, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol and Hepatol. 2015;13:1337-45.e6.CrossRef
79.
Westphalen AC, Qayyum A, Yeh BM, et al. Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology. 2007;242:450–455.CrossRefPubMed
80.
Radmard AR, Poustchi H, Dadgostar M, et al. Liver enzyme levels and hepatic iron content in fatty liver: a noninvasive assessment in general population by T2* mapping. Acad Radiol. 2015;22:714–721.CrossRefPubMed
81.
Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448–457.CrossRefPubMedPubMedCentral
82.
Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999;31:421–429.CrossRefPubMed
83.
Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138:905–912.CrossRefPubMed
84.
Adams PC. The (il) logic of iron reduction therapy for steatohepatitis. Hepatology. 2015;62:668–670.CrossRefPubMed
85.
Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37:720–729.CrossRefPubMed
86.
Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591–8638.CrossRefPubMedPubMedCentral
87.
St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855–861.CrossRefPubMed
88.
Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460–1465.CrossRefPubMedPubMedCentral
89.
Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113:4853–4855.CrossRefPubMedPubMedCentral
90.
Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16:40.CrossRefPubMedPubMedCentral
91.
McCarville MB, Hillenbrand CM, Loeffler RB, et al. Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload. Pediatr Radiol. 2010;40:1360–1367.CrossRefPubMedPubMedCentral
92.
Liau J, Shiehmorteza M, Girard OM, Sirlin CB, Bydder M. Evaluation of MRI fat fraction in the liver and spine pre and post SPIO infusion. Magn Reson Imaging. 2013;31:1012–1016.CrossRefPubMedPubMedCentral
93.
Towbin AJ, Serai SD, Podberesky DJ. Magnetic resonance imaging of the pediatric liver: imaging of steatosis, iron deposition, and fibrosis. Magn Reson Imaging Clin N Am. 2013;21:669–680.CrossRefPubMed
94.
Yokoo T, Browning JD. Fat and iron quantification in the liver: past, present, and future. Top Magn Reson Imaging. 2014;23:73–94.CrossRefPubMed
95.
Hope TA, Ohliger MA, Qayyum A. MR imaging of diffuse liver disease: from technique to diagnosis. Radiol Clin N Am. 2014;52:709–724.CrossRefPubMed
96.
Yoon JH, Lee JM, Suh K-S, et al. Combined use of MR fat quantification and MR elastography in living liver donors: can it reduce the need for preoperative liver biopsy? Radiology. 2015;276:453–464.CrossRefPubMed
97.
Pavlides M, Banerjee R, Sellwood J, et al. Multi-parametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308–315.CrossRefPubMedPubMedCentral
Metadaten
Titel
Quantitative Imaging Biomarkers of NAFLD
verfasst von
Sonja Kinner
Scott B. Reeder
Takeshi Yokoo
Publikationsdatum
05.02.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4037-1

Weitere Artikel der Ausgabe 5/2016

Digestive Diseases and Sciences 5/2016 Zur Ausgabe

Review

Novel Pharmacotherapy Options for NASH

Review

Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease

Review

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD

Review

Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations

Review

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis

Review

Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise